GLPwatch
Papers (10401)
Page 64 of 174, ranked by citation count.
- Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.
- Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.
- The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice.
- Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.
- Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis.
- GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.
- Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
- Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p<sup>66</sup>Shc.
- The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.
- Adult Murine Pancreatic Progenitors Require Epidermal Growth Factor and Nicotinamide for Self-Renewal and Differentiation in a Serum- and Conditioned Medium-Free Culture.
- The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.
- GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model.
- An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides.
- The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
- Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.
- Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.
- Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025).
- Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.
- PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.
- Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
- Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study.
- Tirzepatide-Friend or Foe in Diabetic Cancer Patients?
- The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case-Control Study.
- A pooled analysis of exenatide use and risk of acute pancreatitis.
- Effect of placental restriction and neonatal exendin-4 treatment on postnatal growth, adult body composition, and in vivo glucose metabolism in the sheep.
- Liraglutide for the treatment of type 2 diabetes.
- The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew).
- Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus: Exenatide Use Mediates Depressive Scores Through Increased Perceived Stress Levels.
- The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism.
- Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice.
- Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.
- Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
- Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.
- Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.
- Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
- A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.
- Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism.
- Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
- What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review.
- Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
- Origin and convergent evolution of exendin genes.
- Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
- Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome.
- Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.
- Incretin-based therapy and the quest for sustained improvements in β-cell health.
- L-Carnitine and extendin-4 improve outcomes following moderate brain contusion injury.
- Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.
- Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
- Obesity medications: A narrative review of current and emerging agents.
- Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension.
- GREATER COMBINED REDUCTIONS IN HbA<sub>1C</sub> ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
- Evaluation of [<sup>68</sup>Ga]DO3A-VS-Cys<sup>40</sup>-Exendin-4 as a PET Probe for Imaging Human Transplanted Islets in the Liver.
- Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.
- Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
- Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
- Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
- Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.